Silence Therapeutics
Update in progressSLN (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Silence Therapeutics plc is a London-based biotechnology company focused on discovering and developing siRNA therapies that silence disease-causing genes. Its pipeline includes Divesiran (SLN124) in Phase 2 for polycythemia vera, SLN548 for complement-mediated renal disease, Zerlasiran (SLN360) for cardiovascular disease linked to elevated lipoprotein(a), SLN312 for dyslipidemia, SLN365 for hypercholesterolemia, and SLN098 for obesity. It was SR Pharma plc until 2007; founded in 1994.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited Kingdom
- CEOMr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
- Founded1994
- Employees88
- Websitewww.silence-therapeutics.com
Identifiers
- ISINUS82686Q1013
- FIGIBBG00WVTHPN2
- CUSIP82686Q101
- CIK0001479615